The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.
 
Kunal Desai
Stock and Other Ownership Interests - Agent Capital; Co-D Therapeutics
Consulting or Advisory Role - Agent Capital; Sorrento Therapeutics
 
Anthony V. Serritella
No Relationships to Disclose
 
Walter Michael Stadler
Leadership - EMA Wellness
Consulting or Advisory Role - AstraZeneca; Bayer; Calico; CVS Caremark; Eisai; Merck; Pfizer; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Expert Testimony - Teva
Other Relationship - American Cancer Society; UpToDate
 
Peter H. O'Donnell
Honoraria - Astellas Pharma; Axiom Healthcare Strategies; CLD, Inc.; Curio Science; EMD Serono; FirstWord; Great Debates and Updates; Institute for Enquiring Minds; IntrinsiQ; ISMIE; MedLearning Group; Merck; MJH Life Sciences; NAMCP; Peerview; Pfizer; Research to Practice; SeaGen; Vaniam Group
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
Expert Testimony - Oregon Health & Science University (OHSU)
Travel, Accommodations, Expenses - Curio Science
Other Relationship - Dragonfly Therapeutics; G1 Therapeutics; Janssen; Nektar; NIH
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO; Bristol-Myers Squibb/Medarex; Eisai; Exelixis; Seattle Genetics/Astellas
Consulting or Advisory Role - AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Janssen Oncology; Mirati Therapeutics; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); Pyxis (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma; Pfizer/Astellas
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Novartis; Pfizer; Sanofi
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Harpoon therapeutics (Inst); Janssen Oncology (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Plexxikon (Inst); Progenics (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics